Hemostatic Efficacy and Safety of Weight-Based Versus Fixed-Dose 4F-PCC for Vitamin K Antagonist Reversal
Journal of Pharmacy Practice · 2024
DOI: 10.1177/08971900241228779 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Pharmacy Practice, 2024. Verfasst von Ashley E Milkovits und 4 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacy Specialist, Department of Pharmacy, Carilion Roanoke Memorial Hospital, Roanoke, VA, USA. Hauptthemen laut MEDLINE: Vitamin K, Blood Coagulation Factors, Hemostatics, International Normalized Ratio. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben.
Abstract (Originalsprache)
Background
Four-factor prothrombin complex concentrate (4F-PCC) is indicated for vitamin K antagonist (VKA) reversal but is associated with thrombotic events (TE). In 2018, the institution revised 4F-PCC dosing for VKA reversal from INR and weight-based dosing to a fixed-dose of 1500 units.
Objective
The purpose of this study was to compare hemostatic efficacy and TE rate of fixed-dose 4PCC to weight-based dosing.
Methods
This was a retrospective, single-center, quasi-experimental study of adult patients who received 4F-PCC for VKA reversal from January 2014 through May 2016 (INR and weight-based dosing) or April through October 2018 (fixed-dosing). The primary endpoint was hemostatic efficacy, defined by achieving an INR of ≤1.4, or an INR of ≤1.7 with evidence of hemostasis. The key secondary endpoint was TE within 14 days of 4F-PCC administration. Data were analyzed using descriptive statistics, chi-squared for nominal data and Mann-Whitney U for ordinal and continuous data.
Results
The study included 163 patients who received weight-based dosing and 45 who received fixed-dose 4F-PCC. Hemostatic efficacy was 76.9% of patients in the weight-based group and 77.4% of patients in the fixed-dose group ( P = .229). TE occurred in 13.5% of the weight-based vs 6.7% of the fixed-dose group ( P = .181).
Conclusion
This study found no difference in hemostatic efficacy with fixed-dose 4F-PCC for VKA reversal compared to INR and weight-based dosing. The occurrence of TE was reduced by 50% with the 4F-PCC fixed-dose strategy; however, this difference was not statistically significant. Further randomized studies are needed to confirm these results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacy Specialist, Department of Pharmacy, Carilion Roanoke Memorial Hospital, Roanoke, VA, USA.
- Clinical Pharmacy Coordinator, Duke Raleigh Hospital, Raleigh, NC, USA.
- Clinical Pharmacy Specialist, Parkland Health, Dallas, TX, USA.
- Clinical Pharmacy Manager, Carilion Roanoke Memorial Hospital, Roanoke, VA, USA.
ORCID-Profile: Ashley E Milkovits, David Sugrue
Zitieren
APA
Milkovits, A. E., Sugrue, D., Faris, J., Schad, J. L., & McAllister, K. B. (2024). Hemostatic Efficacy and Safety of Weight-Based Versus Fixed-Dose 4F-PCC for Vitamin K Antagonist Reversal. Journal of Pharmacy Practice. https://doi.org/10.1177/08971900241228779
Vancouver
Milkovits AE, Sugrue D, Faris J, Schad JL, McAllister KB. Hemostatic Efficacy and Safety of Weight-Based Versus Fixed-Dose 4F-PCC for Vitamin K Antagonist Reversal. Journal of Pharmacy Practice. 2024. doi:10.1177/08971900241228779
BibTeX
@article{Milkovits2024,
author = {Milkovits, Ashley E and Sugrue, David and Faris, Janie and Schad, Jessica L and McAllister, Kelly B},
title = {Hemostatic Efficacy and Safety of Weight-Based Versus Fixed-Dose 4F-PCC for Vitamin K Antagonist Reversal},
journal = {Journal of Pharmacy Practice},
year = {2024},
doi = {10.1177/08971900241228779}
}
EUVIMED